Bleomycin Pulmonary Toxicity in Patients with Germ Cell Tumors Treated with Bleomycin Containing Regimens: Experience with 4 Cases
Clicks: 2
ID: 311534
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #207 of 254 articles by views in Yemen Journal of Medicine
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background: Information on Bleomycin pulmonary toxicity (BPT) in Qatar is scarce. The aim of this study was to estimate the prevalence of BPT and to describe its clinical significance and outcome in germ cell tumor (GCT) patients who received bleomycin-containing regimens.
Methods: This retrospective cross-sectional study was conducted at the National Center for Cancer Care and Research. It included all patients diagnosed with GCT and treated with a bleomycin-containing regimen between January 2002 and December 2008
Results: We identified fourteen patients with GCT who received bleomycin containing regimen. Four of them (28.5%) had developed BPT, and they were males with mean age of 39.3±8.3 years (range: 25-46 years). The calculated creatinine clearance before treatment was normal in the 4 cases. Evaluation of the chest computed tomography scan before starting bleomycin containing regimens revealed that none of our patients had pre-existing parenchymal lung disease. The mean cumulative bleomycin dose was 187.5± 153.7 U, while the mean time to onset of BPT was 3.5±2.1 months. Once the diagnosis of BPT was established, bleomycin was discontinued in the four patients and short courses of dexamethasone were administered. Two patients (50%) died, while one patient survived with a fibrosis sequel, and the fourth patient recovered without a fibrosis sequel.
Conclusion: BPT is one of the life-threatening side effects of this drug that every doctor should be aware of when treating GCT, therefore, a high index of suspicious is needed for early recognition of BPTs.
| Reference Key |
ahmed2026bleomycin
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mohammed Sadiq Ahmed, Mohammad Abdel Daem Yassin, Rawan Ahmed Mohammed, Aveen Sadiq, Abdurahman Mustafa Kday |
| Journal | Yemen Journal of Medicine |
| Year | 2025 |
| DOI |
10.63475/yjm.v4i1.0004
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.